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Abstract
Background: Although previous meta-analyses have examined effects of antidepressants, psychotherapy, and alternative
therapies for depression, the efficacy of these treatments alone and in combination has not been systematically compared.
We hypothesized that the differences between approved depression treatments and controls would be small.
Methods and Findings: The authors first reviewed data from Food and Drug Administration Summary Basis of Approval
reports of 62 pivotal antidepressant trials consisting of data from 13,802 depressed patients. This was followed by a
systematic review of data from 115 published trials evaluating efficacy of psychotherapies and alternative therapies for
depression. The published depression trials consisted of 10,310 depressed patients. We assessed the percentage symptom
reduction experienced by the patients based on treatment assignment. Overall, antidepressants led to greater symptom
reduction compared to placebo among both unpublished FDA data and published trials (F=38.5, df=239, p,0.001). In the
published trials we noted that the magnitude of symptom reduction with active depression treatments compared to
controls was significantly larger when raters evaluating treatment effects were un-blinded compared to the trials with
blinded raters (F=2.17, df=313, p,0.05). In the blinded trials, the combination of antidepressants and psychotherapy
provided a slight advantage over antidepressants (p=0.027) and psychotherapy (p=0.022) alone. The magnitude of
symptom reduction was greater with psychotherapies compared to placebo (p=0.019), treatment-as-usual (p=0.012) and
waiting-list (p,0.001). Differences were not seen with psychotherapy compared to antidepressants, alternative therapies or
active intervention controls.
Conclusions: In conclusion, the combination of psychotherapy and antidepressants for depression may provide a slight
advantage whereas antidepressants alone and psychotherapy alone are not significantly different from alternative therapies
or active intervention controls. These data suggest that type of treatment offered is less important than getting depressed
patients involved in an active therapeutic program. Future research should consider whether certain patient profiles might
justify a specific treatment modality.
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Introduction
A number of recent articles have emphasized the inability of
antidepressant medication to consistently demonstrate superiority
to placebo pills [1–4]. Approximately half of clinical trials fail to
differentiate active treatments from controls, and mean differences
between drug and placebo on the Hamilton Rating Scale for
Depression are small [2,5]. This phenomenon has sparked
considerable concern and criticism from the popular media,
clinicians and researchers [6,7].
Psychotherapies for depression have also come under scrutiny
for their inability to demonstrate substantial superiority to various
treatment controls as opposed to waiting-list (no treatment)
controls [8]. Similarly, although alternative therapies such as
acupuncture and exercise have shown promise in individual
published studies [9,10], the profile is less impressive according to
independent reviews such as Cochrane Reviews [11,12] and those
conducted by the National Institute for Health and Clinical
Excellence [13].
Given this level of ambiguity, it is unclear if pharmacological
treatments are any better or worse than psychotherapies or if
psychotherapies are any better than non-traditional treatments
such as exercise and acupuncture. Thus, we undertook to critically
evaluate relative efficacy among the various treatments for
depression along with control procedures, including placebo pills.
To provide a relatively unbiased perspective of the response to
treatments for depression, we used as an anchor the clinical trial
data from pivotal antidepressant trials that had been submitted to
the United States Food and Drug Administration (FDA) during
the drug approval process. Because drug companies are required
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e41778to submit information on all of the trials they conducted, these
data should be free of publication and author bias [3].
Furthermore, these trials all contain data on placebo response in
depression, were conducted at multiple sites and the data were
accumulated over the past three decades.
Following the establishment of the anchor we conducted a
literature search identifying depression clinical trials conducted
over the past thirty-five years. We specifically evaluated data from
depression trials that were designed to assess the role of
antidepressants, psychotherapies, active intervention, and control
treatments including placebo.
Our hypothesis was that the differences between the various
depression treatments and controls would be relatively small. We
additionally hypothesized that any differences in efficacy among
these treatments would be further reduced if we applied stringent
criteria for the ‘blinded’ status of the trial. This hypothesis is based
on earlier reviews [8,14–16] as well as our own reviews of
antidepressant and placebo data from pivotal antidepressant
clinical trials [2,5].
In order to verify our hypothesis, we focused on evaluating the
reduction of depressive symptoms experienced during depression
trials by the patients assigned to the various active depression
treatments and treatment controls. We controlled for rater bias by
comparing the reduction of symptoms from depression trials with
raters/clinicians who knew the study design, intent and potential
treatment assignments compared to depression trials that included
raters/clinicians who were blinded to these factors. As part of this
exploration, we compared the antidepressant-placebo differences
among unpublished, industry sponsored data obtained from the
US FDA with published reports that were not sponsored by
industry. Also, we evaluated if there were significant differ-
ences in the magnitude of symptom reduction among various
psychotherapies.
Methods
Selection of Depression Trials for Evaluation
During New Drug Approval process the US FDA reviews trial
level efficacy and safety data from pivotal clinical trials conducted
during development programs of putative medications. In 1997
the data used by the FDA during the risk/benefit evaluations
became available to the public via the Freedom of Information Act
[17]. Summary Basis of Approval (SBA) reports detail data from
the medication development programs and are available directly
from the FDA website at www.fda.gov. If SBA reports are not
available at the FDA website, the FDA staff provides data on
CDRom in response to written requests.
As first part of our selection of depression treatment trials, we
accessed antidepressant trial data that were reviewed by the
physicians, scientists and statisticians at the FDA and reported in
SBA reports. All of the data were from pivotal, placebo controlled
trials that the FDA used to approve eleven antidepressants
between 1987 and 2004. The efficacy dataset from these trials
consisted of sixty two antidepressant clinical trials conducted
between 1979 and 2001 that included 13,802 depressed patients
[18,19,20].
Aside from this FDA data, we reviewed published literature
regarding the efficacy data for traditionally accepted non-
medicinal depression treatments and controls. We first searched
the published literature for controlled trials of cognitive, behav-
ioral, cognitive behavioral psychotherapies and derivatives of these
treatments for major depressive disorder, dysthymia or postpartum
depression. Following this search, we conducted a similar search
for controlled trials of alternative therapies (exercise and acu-
puncture) for depression.
Inclusion and Exclusion of Published Depression Trials
During the span of time when these depression trials were
conducted there were three versions of the Diagnostic and
Statistical Manual (DSM) of the APA. These consisted of DSM-
II [21], DSM-III [22] and DSM-IV [23]. In essence there are no
differences in the diagnostic criteria between DSM-III and DSM-
IV for major depression. However, there were significant
differences in the scope and definition of depression between
DSM-II and DSM-III.
In order to decrease any heterogeneity, we specifically evaluated
the data from trials (n=19) that were conducted prior to the full
establishment and incorporation of DSM-III that was introduced
in 1978. We specifically evaluated if the precursors of DSM-III,
notably Research Diagnostic Criteria (RDC) [24] or Feighner
Criteria [25] were used during diagnosis. These criteria were in
fact considerably narrower than DSM-III. Four of these 19 trials
used Feighner criteria and five of the nineteen used RDC criteria.
Among the rest (n=10), we included the data, if specific clinical
evaluations described the sample in sufficient detail to formulate
DSM-III diagnostic criteria.
Although we did not follow a published pre-specified protocol
during our systematic review, the trial inclusion/exclusion criteria,
search stategy and primary outcome variable were defined a-priori
(the Prisma 2009 Checklist is Figure S1). We targeted manuscripts
describing depression trials of traditionally accepted and estab-
lished psychotherapies or alternative therapies for Major Depres-
sive Disorder including the depression disorder subtypes dysthy-
mia and postpartum depression. The published trials were
representative of clinically depressed ambulatory adults between
the ages of 18 and 65 years of age.
We included trials that reported acute depression treatment
outcomes using the Hamilton Rating Scale for Depression
(HRSD), Beck Depression Inventory (BDI), or Montgomery-
Asberg Depression Rating Scale (MADRS). Trials that reported
an outcome in figure format were included if we were able to
estimate mean total baseline and end of acute treatment outcomes
from the figure.
Exclusion criteria were as follows: 1) Trials that primarily
enrolled patients that were under the age of 18 or over the age of
65, 2) Trials that targeted depressed patients with major medical
or psychiatric co-morbidities (e.g., human immunodeficiency
virus, cancer, cardiovascular disease, patients in recovery from
stroke, patients with co-morbid substance abuse), 3) Trials that did
not evaluate and report treatment outcome within one week of
patient of completion of treatment, 4) Trials targeting treatment
resistant or hospitalized depressed patients, 5) Trials with
incarcerated depressed patients, 6) Trials that were not published
in the English language. Trials that were not reported in peer-
reviewed journals (for example, dissertations) were also excluded.
Trials that did not report the mean baseline symptom
evaluation and treatment outcome using the HRSD, MADRS
or BDI were excluded. We also excluded trials that did not include
an active treatment arm with a traditionally accepted psychother-
apy. For example, we excluded trials that targeted experimental
therapies such as bibliotherapy (telephone therapy) or computer
implemented therapy without including an active treatment arm.
Identification of Depression Trials in the Published
Literature
Our primary strategy during the search for published depression
treatment trials was to use a ‘‘snowball search’’ of the numerous
Efficacy of Treatments for Depression
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alternative treatments for depression.
Our literature search was conducted from September to
December 2010, and targeted trials that were published between
1975 and 2009. We began by reviewing several meta-analyses
designed to evaluate efficacy outcomes between psychotherapy
and other treatments and controls for depression including other
psychotherapies, alternative therapies, combination therapies,
antidepressants, and placebos or active intervention controls
[8,16,,26,27,28,29]. During this search we identified a database
of 243 psychotherapy trials compiled by Dr. Pim Cuijpers and his
depression research group at www.evidencebasedpsychotherapies.
org [30]. Throughout this process we retrieved title and abstract
of all psychotherapy for depression trials that were used for the
meta-analyses and reviews as well as those from the website by
Cuijpers et al.
We then conducted a similar search targeting published
controlled trials of alternative therapies for depression. We
conducted this second ‘‘snowball search’’ by accessing Cochrane
Reviews website and obtaining recently completed reviews of trials
of exercise and acupuncture for treatment of major depressive
disorder, dysthymia or postpartum depression [11,12]. We
retrieved title and abstract for each article that was included in
the Cochrane Group evaluation of efficacy of exercise or acu-
puncture for depression.
After the ‘‘snowball search’’ of previously conducted reviews of
published psychotherapy, exercise and acupuncture trials we
conducted an additional online search for recently completed trials
that may have been overlooked. We accessed Pubmed, Psychinfo
and the Cochrane Register of Controlled Trials. We conducted
identical searches in each database entering in turn the keywords
acupuncture, exercise, and relaxation for trials of alternative
therapies. For the psychotherapy trials we entered in turn the
keywords psychotherapy, cognitive, behavioral, cognitive-behav-
ioral, rational-emotive, and interpersonal. The terms ‘‘depression
and placebo’’ or ‘‘depression and controlled’’ were used
interchangeably in combination with the specific therapy names
within each search engine.
For this search, we did not search for or include industry
sponsored antidepressant trials that used a placebo control with an
antidepressant, or that compared multiple antidepressants with no
other established depression treatments, to avoid duplication of the
FDA data. We only included antidepressant data from published
trials of psychotherapy or alternative therapies for depression trials
identified during the literature search outlined above. The
antidepressant data from the published sources were independent
from the pivotal registration trials that were reviewed by the FDA.
Organization of Data
The ‘‘snowball search’’ strategy produced 310 abstracts of
depression treatment trials following our searches of previously
published reviews, analyses and the website by Cuijpers et al. We
reviewed the title and abstract of each article retrieved. Articles
were retrieved and fully reviewed if they were available as English
publications and did not specifically target depressed patients with
physical or psychiatric co-morbidities such as Human Immuno-
deficiency Virus, cancer, cardiovascular disease, Bipolar Disorder,
or Psychotic Spectrum Disorders. The PRISMA flow chart
depicting process of exclusion for the published depression
treatment trials is shown as Figure 1.
We included 106 trials from the search of previously published
reviews and meta-analyses of published depression treatment
trials. We identified an additional 9 trials with the online literature
search. The list of references for the 115 depression treatment
trials included in our study is shown as Appendix S1.
There were 328 treatment arms that enrolled 10,310 depressed
patients in the 115 published depression treatment trials. Based on
description by study authors, we identified four active treatments
and four treatment controls. As shown in Table 1, the active
depression treatments consisted of 218 trial arms enrolling 7,683
patients. Treatment controls consisted of 110 arms enrolling 2,627
patients.
The active treatments and controls, as described by the authors,
are shown as Appendix S2. The active treatments were: 1)
antidepressants in combination with psychotherapies or alternative
treatments, 2) antidepressants with minimal clinical management,
3) psychotherapies alone that are considered to be accepted
depression treatments (cognitive-behavioral, cognitive and behav-
ioral therapies and author described derivatives), and 4) a group of
treatments traditionally accepted as alternative therapies for
depression. The specific names of active treatments are shown as
Appendix S2 Parts1–4.
The control treatments were: 1) placebo pills, 2) procedures
designated by trial authors as active intervention controls (e.g.,
sham acupuncture, therapies not specific to depression, partial
presentations of full therapy regimens), 3) treatment-as-usual,
which consisted of care by the primary care physicians or referrals
to general practitioners and which may have included pre-
scriptions for antidepressants, and 4) waiting-list controls. The
specific names of the treatment controls are shown as Appendix S2
Parts 5–8.
Designation of Blinded Status
As has been shown by several groups of researchers, the
outcomes of depression trials are significantly influenced by design
factors that shape the expectations of clinicians and depressed
patients [31–33]. Other investigators [8,14] have attempted to
quantify such a possibility by evaluating the evaluator. Specifically,
these earlier investigators evaluated outcome of depression trials
based on the level of control that was built into trial design by
blinding the symptom evaluator.
To evaluate any impact of blinding on trial outcome we used
the following procedures to quantify trials as blinded or un-
blinded. First, we categorized as un-blinded data from all of the
depression trials that used patient ratings (BDI scale scores) as the
primary dependent measure. We based this decision on the
findings of Prioleau et al. that the largest treatment effects of
psychotherapy relative to placebo came from studies that used
undisguised self-report [14].
Second, for all trials that reported mean change in HRSD or
MADRS scores we categorically evaluated the clinician/raters at
the end of treatment evaluation as blinded or un-blinded following
the methods outlined by Cuijpers et al. [8]. We categorized as
blinded the trials that specifically described assessors at the end of
treatment as independent from and blinded to the condition to
which depressed patients were assigned. The trials with HRSD
and MADRS that did not specify an independent symptom
assessor were categorized un-blinded.
The depression trials that assigned patients to pill placebo were
all categorized as blinded. Each of these trials specified that
symptom assessor at end of treatment was blinded to patient
assignment to antidepressant or placebo. Based on this type of
demarcation, we subdivided the 115 depression treatment trials
into two groups; termed group 1 with un-blinded raters (k=59)
and group 2 with blinded raters (k=56).
Efficacy of Treatments for Depression
PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e41778Figure 1. Process of Exclusion of Trials Identified During Search of Depression Treatment Reviews and Analyses, and the Website
by Cuijpers and Colleagues.
doi:10.1371/journal.pone.0041778.g001
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Our analysis of data was designed to evaluate the relative
efficacy of the active depression treatments and controls and to
evaluate the impact that blinding the trial has on treatment
outcomes. We chose the mean percentage symptom reduction as
our primary outcome measure. Our selection of this outcome was
based on the data available as several of the published depression
trials included multiple treatment arms with a single control arm
violating assumptions necessary to calculate an independent effect
size. There were also trials that simply did not report data from
which an effect size could be calculated.
In the event that a trial reported more than one outcome
measure (for example, some trials reported BDI and HRSD
outcome), we selected for evaluation the clinician administered
measure. Where available we recorded the Intent-to-Treat out-
come, although in some cases there were not ongoing assessments
throughout the trial in which case the Completer Only results were
included for analysis.
The mean weighted percentage symptom reduction as a
function of blinding, therapy type, and data source for each
treatment and control is displayed in Figure 2. As a preliminary
analysis, we compared the antidepressant and placebo data from
published non-industry depression trials to the placebo controlled
antidepressant registration trials from the FDA dataset. We
conducted a 2 factor univariate analysis of variance (ANOVA).
We entered as binomial independent variables the data source
(1=published data, 2=FDA data) and the comparison of
antidepressant (coded 1) versus placebo (coded 2) with percentage
symptom reduction being the primary outcome measure.
This was followed by a 268 ANOVA of the published
depression trials to evaluate the role of blinding and type of
treatment on outcome for the depressed patients. To conduct this
ANOVA, we entered the blinding status(1=un-blinded, 2=blind-
ed) and treatment type (combination=1, antidepressant=2,
psychotherapy=3, alternative therapy=4, intervention con-
trol=5, placebo control=6, treatment as usual=7, waiting
list=8) as independent variables and the percentage symptom
reduction was the dependent variable.
Comparative efficacy between treatment outcomes was ana-
lyzed with separate one-way ANOVAs on treatment type with
blinded and un-blinded studies, respectively. Tukey’s Least
Significant Difference post-hoc test was used to evaluate signifi-
cance of any differences in percentage symptom reduction
between the 4 active depression treatments and 4 treatment
controls.
Lastly, we compared outcome of the psychotherapy treatment
arms based on psychotherapy type. We conducted 265 ANOVA
to evaluate impact of blinded status or psychotherapy type on
outcome for the psychotherapy trial arms. We coded psychother-
apy trial arms specifying use of Cognitive Behavioral Therapy
(CBT) with 1, Cognitive Therapy with 2, and Behavioral Therapy
with 3 and Interpersonal Psychotherapy with 4. Other therapies
(e.g., Rational-emotive Therapy, Self-Control Therapy, Assertive-
ness Training, Post-Partum Support Group) were coded 5. The
percentage symptom reduction was again used as dependent
outcome measure weighted by number of patients. All analyses
were conducted using SPSS version 19.0 (IBM).
Results
The preliminary comparison of percentage symptom reduction
with antidepressant and placebo treatment arms from published
trials to antidepressant and placebo data from the FDA files
revealed two significant main effects. The ANOVA indicated that
antidepressants resulted in significantly greater symptom reduction
than placebo, F(df=239)=38.5,p,.001. There was also a
significant main effect of data source, F(df=241)=33.6,p,.001.
Percentage symptom reduction was higher for published antide-
pressant (published data=51%, FDA data 42=%) and placebo
Table 1. Summary Data from Depression Treatment Trials Based on Type of Treatment and Source of Data.
Treatment Type and Source Number of Treatment Arms Number of Patients
FDA Summary Basis of Approval Reports
Investigative Agents 80 7,014
Active Comparators 31 2,220
Placebo Controls 57 4,568
Column Totals 168 13,802
Published Depression Treatment Trials
Active Treatments
Combination Therapy + Antidepressants 32 1,249
Antidepressants + Clinical Management 40 1,958
Accepted Psychotherapies for Depression 128 4,034
Alternative Therapies for Depression 18 442
Column Totals 218 7,683
Treatment Controls
Pill Placebo Controls 16 412
Intervention Controls 48 1,095
Treatment as Usual Controls 12 530
Waiting-list Controls 34 590
Column Totals 110 2,627
Specific names of treatment arms for accepted depression treatments and treatment controls are shown as Appendix B.
doi:10.1371/journal.pone.0041778.t001
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reported in the FDA SBA reports. The interaction between
treatment type and data source was not significant, p=0.313 (see
Figure 2).
The 268 ANOVA to evaluate the role of blinding and the type
of treatment on outcome in the published trials revealed a
significant main effect of treatment type, F(df=313)=33.7,
p,0.001, and a significant interaction between treatment type
and blinded status, F(df=313)=2.17, p=0.045. Treatment type
was a significant predictor of percentage symptom reduction in
both un-blinded and blinded trials, but the magnitude and pattern
of significance differed as a function of blinding.
As shown in Figure 2, the impact of blinding was most obvious
in combination therapy trials with un-blinded trials resulting in
66% percentage symptom reduction versus 53% in blinded trials.
The un-blinded trials also resulted in greater symptom reduction
for antidepressants, psychotherapy and intervention controls. On
the other hand, treatment-as-usual resulted in 24% symptom
reduction for un-blinded trials with 36% symptom reduction in
blinded trials.
Results from the separate one way ANOVAs to evaluate
percentage symptom reduction between treatments and controls
are shown as Tables 2 and 3. As shown in Table 2, in un-blinded
trials combination antidepressant + therapy resulted in greater
percentage symptom reduction than psychotherapy and antide-
pressants alone and all of the treatment controls. There were no
significant differences in percentage symptom reduction between
antidepressants, psychotherapy and alternative therapy. Psycho-
therapy and antidepressants were superior to all of the control
treatments. There was no evidence of heterogeneity of outcomes
across groups of un-blinded depression treatment arms based on
Levene’s Test of Equality of Error Variance, F=1.82 (df=150),
p=0.099.
As shown in Table 3, in blinded trials combination therapy was
superior to psychotherapy and antidepressants alone and all of the
treatment controls. There were no significant differences in
percentage symptom reduction between psychotherapy, antide-
pressants, alternative therapies, and active intervention controls.
Antidepressants, psychotherapy and active intervention controls
resulted in greater percentage symptom reduction than the
placebo controls, treatment-as-usual and wait-list. There was no
evidence of heterogeneity of outcomes across groups of blinded
depression trials based on Levene’s Test of Equality of Error
Variance, F=1.02 (df=163), p=0.420.
There were no significant differences in percentage symptom
reduction based on psychotherapy type as shown in Figure 3,
F(df=128)=1.42, p=0.23. There was a significant main effect of
blinding, F(df=128)=4.11,p=0.045.
Discussion
Much has been made of the inability of antidepressants to
demonstrate clinically significant superiority to placebo in
antidepressant clinical trials. The aim of this study was to compare
the efficacy of combination psychotherapy + antidepressant,
antidepressants, psychotherapies, alternative therapies and con-
trols including placebo control for depression. We also evaluated
the role of blinding as a factor in assessing differences between
treatments.
Figure 2. Mean Percentage Symptom Reduction from Un-blinded and Blinded Treatment Arms from Published Depression Trials
Compared to Data from Pivotal Registration Depression Trials as Reported by the FDA. Red Bars Represent Un-Blinded Trial Arms Blue
Bars Represent Blinded Trial Arms Yellow Represents Placebo Control Arms from Published Non-Registration trials Green Bars Represent Data from
Pivotal Registration Trials The mean percentage symptom reduction was weighted by the number of assigned patients. Error Bars Represent 95%
Confidence Intervals. Active treatment arms consist of combination antidepressant + therapy, antidepressants, psychotherapy, antidepressant
therapy and alternative therapy. Control treatment arms consisted of placebo control, active intervention control, treatment-as-usual and waiting-list
control. Blinded trials were operationally defined as those that utilized depression symptom raters that were blinded to treatment assignment of the
patients.
doi:10.1371/journal.pone.0041778.g002
Efficacy of Treatments for Depression
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PLoS ONE | www.plosone.org 8 July 2012 | Volume 7 | Issue 7 | e41778Not surprisingly, blinding tended to decrease improvement in
active treatment arms and increase it in control arms. This finding
replicates previous analyses that have evaluated treatments by
quantifying the level of blinding [8,14] suggesting that study design
features do impact outcome of psychotherapy trials.
More importantly, when the raters were blinded the combined
treatment of psychotherapy plus antidepressants showed only a
slight advantage to antidepressants or psychotherapies alone.
Although antidepressants alone and psychotherapy alone did differ
significantly from placebo controls, treatment-as-usual and waiting
list controls, they did not differ from alternative therapies such as
exercise and acupuncture or active treatment control procedures.
It is interesting to note that although combination therapy did
not statistically separate from exercise and acupuncture in the
blinded trials, these alternative therapies themselves were not
statistically superior to placebo (p=0.066). This may be due to the
small number of trials evaluating these. Aside from this fact, there
is no obvious explanation for the increased variability in outcome
observed in exercise and acupuncture treatment arms. Although
the surface features of psychotherapy, antidepressants, exercise
and acupuncture are very different, they do result in similar
reduction of depressive symptoms and may have the same
mechanism of action. The lack of significant differences between
very diverse active treatments suggests that non-specific therapeu-
tic factors may account for a large part of the effectiveness of these
depression treatments.
Frank and Frank [34] contend that it is difficult to attribute
specific outcomes to active therapies due to common therapeutic
factors that patients experience during treatment. They undergo a
thorough evaluation, are provided with an explanation for their
distress, develop an expectation for improvement, and participate
in a therapeutic ritual with an expert healer. These factors are the
common threads among the conception and execution of these
otherwise heterogeneous depression trials and treatments. Al-
though such non-specific effects have been noted with comparisons
of different psychotherapies for over 70 years [35,36], our study is
the first to note such outcome similarities across such a diverse
group of treatments and controls for depression.
One possible reason for the lack of assay sensitivity in depression
trials is that common therapeutic factors are not exclusive to active
depression treatments. Although the placebo pill is in essence inert
and active intervention controls are devoid of the methodological
rigor of active psychotherapies, the depressed patients assigned to
these conditions are exposed to all other aspects of an active
therapy. This reasoning might explain the finding that patients
experienced similar improvement with placebo pill as compared to
those assigned to treatment as usual that may have included
antidepressants.
Our study has notable limitations with respect to the inferences
that can be drawn from it. We know that patients that enroll in
antidepressant clinical trials are not representative of depressed
patients in clinical practice [37]. Depression trials of psychother-
apy, exercise and acupuncture are also likely to attract a highly
select group of depressed patients [38]. Thus, the generalizability
of these data is limited.
Furthermore, we were not able to evaluate the roll that severity
of depression may have played on treatment outcome. We do
know that a higher severity of depression contributes to increased
antidepressant-placebo differences in antidepressant clinical trials
[33].
These data suggest that the preference of the patient,
accessibility of various treatment options and riskiness of the
therapy should all be factored into depression treatment decisions.
It is important to note, however, that engaging in treatment is
critical to improvement. These factors should be considered
during cost-effectiveness analyses of potential depression treat-
Figure 3. Mean Weighted Percentage Symptom Reduction of Psychotherapy Trial Arms from Published Depression Trials based on
Type of Therapy Administered. The number of treatment arms for each therapy type was 24 for Cognitive Behavioral Therapy (16 un-blinded, 8
blinded), 39 for Cognitive Therapy (22 un-blinded, 17 blinded), 9 for Behavioral Therapy (7 un-blinded, 2 blinded), 14 for Interpersonal Therapy (7 un-
blinded, 7 blinded) and 43 for therapies with other titles (26 un-blinded, 17 blinded).
doi:10.1371/journal.pone.0041778.g003
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PLoS ONE | www.plosone.org 9 July 2012 | Volume 7 | Issue 7 | e41778ments. For example, allowing patients to choose a preferred
treatment from outset during cost-effectiveness studies may have
influence on outcome and associated cost [39,40].
Our results also suggest that interpretation of clinical research
evaluating relative efficacy of depression treatments using the
randomized, double blind paradigm is problematic. With the
exception of waiting-list control and treatment-as-usual, it is
difficult to differentiate active treatments from ‘‘treatment
controls’’ in adequately designed and highly blinded trials. This
suggests alternative paradigms such as relapse prevention designs
should be considered to evaluate potential treatments in the future.
In general, DSM depression is a broad and heterogeneous
diagnosis, and researchers in the future might attempt to uncover
specific profiles of depression which respond differentially to
certain forms of treatment [41,42]. Targeting treatment effects
based on age, gender, weight, pattern of symptoms and
biomarkers may be worth exploring.
In conclusion, our results indicate that in acute depression trials
using blinded raters the combination of psychotherapy and
antidepressants may provide a slight advantage whereas antide-
pressants alone and psychotherapy do not significantly different
from alternative therapies such as exercise and acupuncture or
active intervention controls such as bibliotherapy or sham
acupuncture. These data suggest that type of treatment offered
is less important than getting depressed patients involved in an
active therapeutic program. Thus, treatment type might best be
chosen on the basis of differences in the clinical presentations, risks
and patient preferences and acceptance. Future research should
consider whether certain patient profiles might justify a specific
treatment modality.
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